Avista SPAC (APAC) to Combine with Ligand's OmniAb in Spin-off and Business Combination

Avista Capital Partners Invests in eMolecules

March 25, 2021

Healthcare Services

Avista Capital Partners has signed a definitive agreement to invest in eMolecules, a San Diego–based e-procurement and marketplace platform for high-value chemicals and bioreagents used in drug discovery. Financial terms were not disclosed; Avista said the investment will support eMolecules' growth and expansion into additional biopharma and academic customers.

Avista Capital Partners Acquires Taconic Biosciences

November 1, 2022

Biotechnology

Avista Capital Partners has acquired Taconic Biosciences from H.I.G. Capital. Taconic, a Rensselaer, New York–based provider of genetically engineered murine research models and related preclinical services, will leverage Avista's healthcare investing expertise to pursue organic growth and strategic acquisitions in the GEMs market.

Atlantic Coastal Acquisition Corp. II Completes Business Combination with Abpro Corporation

November 13, 2024

Biotechnology

Abpro Corporation and Atlantic Coastal Acquisition Corp. II completed their business combination and the combined company will operate as Abpro Holdings, Inc., with Abpro Corporation as a wholly owned subsidiary. The company is expected to begin trading on Nasdaq under the ticker ABP (and ABPWW for warrants); South Korea's Celltrion participated in a $5.0 million PIPE and appointed Soo Young Lee to Abpro's board.

Cambrex Acquires Avista Pharma Solutions

January 2, 2019

Pharmaceuticals

Cambrex Corporation completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners in a transaction announced November 20, 2018 and completed January 2019 (reported consideration about $252 million). The deal brings Avista’s early‑stage drug development, analytical/testing and finished dosage capabilities (sites in Longmont, CO; Durham, NC; Agawam, MA; and Edinburgh, UK) into Cambrex’s global CDMO network to expand capabilities and cross‑sell services.

Revelstoke Capital Partners Recapitalizes AOM Infusion

April 15, 2025

Healthcare Services

Revelstoke Capital Partners completed a recapitalization of AOM Infusion, a specialty infusion provider that delivers IVIG, biologics and other therapies for chronic conditions. Revelstoke will support AOM's management team to expand therapeutic focus areas, deepen clinical expertise and grow the company's patient reach; terms were not disclosed.

Avista Healthcare Partners Acquires Trillium Health Care Products

August 7, 2024

Pharmaceuticals

Avista Healthcare Partners has completed the acquisition of Trillium Health Care Products, a Brockville, Ontario-based CDMO specializing in branded over‑the‑counter (OTC) products, from New Water Capital. Avista plans to invest in Trillium’s growth, expand its footprint and capabilities, and use the business as a consumer‑healthcare platform for potential strategic add‑on acquisitions.